XOMA Royalty Corp.
NASDAQ:XOMABiotechnology
+$0.19 today
- Market cap
- $503.77M
- Beta
- 0.87
- P/E (TTM)
- 15.8
- EPS (TTM)
- $2.65
Volume 4.22M
Average 0.21M
Fair Value & DCF
Compare our fair value with your own assumptions
Intrinsic Alpha selects a valuation method suited to the business. Use the calculator below to build an independent scenario with your preferred cash-flow basis.
XOMA Royalty Corp.
NASDAQ:XOMA
Intrinsic Alpha fair value
Locked
Current Price
$40.17
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Build your own valuation
Test an independent scenario and compare it with Intrinsic Alpha's estimate.
Sign in to use the DCF calculator
Free accounts get 5 valuations per week. Upgrade for more.
Growth Analysis
Historical CAGR & forward analyst estimates
| Metric | 10yr | 5yr | 3yr | Fwd Est. |
|---|---|---|---|---|
| EPS | N/A | N/A | N/A | -3.1% (5yr)1 analysts |
| Revenue | N/A | N/A | +105.3% | +8.8% (5yr)1 analysts |
| Net Income | N/A | N/A | N/A | -6.7% (5yr)1 analysts |
| EBIT | N/A | N/A | N/A | N/A1 analysts |
Analysis
Recent growth has been strongest in Revenue at +105.3% over three years. Forward estimates point to Revenue at +8.8% (5yr), giving you a quick check on whether expectations are accelerating or cooling.
Estimates & History
Historical data and analyst estimates. Solid bars are actuals; dashed-border bars are future estimates.
Competitor Valuations
Peer stocks ranked by intrinsic value status
| Company | Market Cap | Price | Valuation | P/E | 1Y Return |
|---|---|---|---|---|---|
Design Therapeutics, Inc. NASDAQ:DSGN | $976.83M | $15.64 | Not rated | -10.7 | +29.64% |
Solid Biosciences Inc. NASDAQ:SLDB | $844.55M | $10.84 | Not rated | -4.3 | +39.37% |
Aura Biosciences, Inc. NASDAQ:AURA | $496.91M | $7.74 | Not rated | -3.7 | +32.16% |
Autolus Therapeutics plc NASDAQ:AUTL | $420.51M | $1.58 | Not rated | -1.4 | -15.50% |
Rocket Pharmaceuticals, Inc. NASDAQ:RCKT | $419.30M | $3.84 | Not rated | -1.7 | -28.23% |
DiaMedica Therapeutics Inc. NASDAQ:DMAC | $410.59M | $7.62 | Not rated | -8.8 | +21.45% |
Benitec Biopharma Inc. NASDAQ:BNTC | $346.99M | $13.22 | Not rated | -12.3 | -39.76% |
Galectin Therapeutics Inc. NASDAQ:GALT | $297.01M | $4.51 | Not rated | -7.1 | -52.99% |
Quantum-Si incorporated NASDAQ:QSI | $184.05M | $0.93 | Not rated | -2.1 | -20.47% |
Continue the stock analysis
Jump to another research area for this company.